Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 32
Filter
1.
Phytopathology ; 113(9): 1716-1728, 2023 Sep.
Article in English | MEDLINE | ID: mdl-37486151

ABSTRACT

A previously uncharacterized torradovirus species infecting potatoes was detected by high-throughput sequencing from field samples from Peru and in customs intercepts in potato tubers that originated from South America in the United States of America and the Netherlands. This new potato torradovirus showed high nucleotide sequence identity to an unidentified isometric virus (SB26/29), which was associated with a disease named potato rugose stunting in southern Peru characterized over two decades ago. Thus, this virus is tentatively named potato rugose stunting virus (PotRSV). The genome of PotRSV isolates sequenced in this study were composed of two polyadenylated RNA segments. RNA1 ranges from 7,086 to 7,089 nt and RNA2 from 5,228 to 5,230 nt. RNA1 encodes a polyprotein containing the replication block (helicase-protease-polymerase), whereas RNA2 encodes a polyprotein cleaved into a movement protein and the three capsid proteins (CPs). Pairwise comparison among PotRSV isolates revealed amino acid identity values greater than 86% in the protease-polymerase (Pro-Pol) region and greater than 82% for the combined CPs. The closest torradovirus species, squash chlorotic leaf spot virus, shares amino acid identities of ∼58 and ∼41% in the Pro-Pol and the combined CPs, respectively. [Formula: see text] Copyright © 2023 The Author(s). This is an open access article distributed under the CC BY 4.0 International license.


Subject(s)
Solanum tuberosum , Solanum tuberosum/genetics , RNA, Viral/genetics , Peru , Genome, Viral , Plant Diseases , Peptide Hydrolases/genetics , Polyproteins/genetics , Amino Acids/genetics , Growth Disorders/genetics
2.
Diabetes ; 70(8): 1640-1653, 2021 08.
Article in English | MEDLINE | ID: mdl-33980693

ABSTRACT

Insulin receptor substrate-1 (Irs1) is one of the major substrates for insulin receptor and insulin-like growth factor-1 (IGF-1) receptor tyrosine kinases. Systemic Irs1-deficient mice show growth retardation, with resistance to insulin and IGF-1, although the underlying mechanisms remain poorly understood. For this study, we generated mice with brain-specific deletion of Irs1 (NIrs1KO mice). The NIrs1KO mice exhibited lower body weights, shorter bodies and bone lengths, and decreased bone density. Moreover, the NIrs1KO mice exhibited increased insulin sensitivity and glucose utilization in the skeletal muscle. Although the ability of the pituitary to secrete growth hormone (GH) remained intact, the amount of hypothalamic growth hormone-releasing hormone (GHRH) was significantly decreased and, accordingly, the pituitary GH mRNA expression levels were impaired in these mice. Plasma GH and IGF-1 levels were also lower in the NIrs1KO mice. The expression levels of GHRH protein in the median eminence, where Irs1 antibody staining is observed, were markedly decreased in the NIrs1KO mice. In vitro, neurite elongation after IGF-1 stimulation was significantly impaired by Irs1 downregulation in the cultured N-38 hypothalamic neurons. In conclusion, brain Irs1 plays important roles in the regulation of neurite outgrowth of GHRH neurons, somatic growth, and glucose homeostasis.


Subject(s)
Brain/metabolism , Growth Disorders/genetics , Growth Hormone-Releasing Hormone/genetics , Hypothalamus/metabolism , Insulin Receptor Substrate Proteins/genetics , Insulin Resistance/physiology , Adipose Tissue, White/metabolism , Animals , Glucose/metabolism , Growth Disorders/metabolism , Growth Hormone/blood , Growth Hormone-Releasing Hormone/metabolism , Homeostasis/physiology , Insulin Receptor Substrate Proteins/metabolism , Insulin-Like Growth Factor I/metabolism , Liver/metabolism , Mice , Mice, Knockout , Muscle, Skeletal/metabolism , Neurons/metabolism
3.
Medicine (Baltimore) ; 100(7): e24712, 2021 Feb 19.
Article in English | MEDLINE | ID: mdl-33607811

ABSTRACT

RATIONALE: The aim of this study was to analyze the genetic abnormalities and clinical manifestations of Shwachman-Diamond syndrome (SDS). PATIENT CONCERNS: A Chinese infant with elevated transaminase and a novel mutation at of sbdsc.258 +2T>C and c.184a>Tc.292G>A. DIAGNOSES: The female patient was 5 months' old at onset, with elevated transaminase as the first manifestation accompanied by restricted growth and development and oily stool. After sequencing the blood samples from patients and their parents, the heterozygous mutations of sbdsc.258 +2T>C and c.184a>T were detected. INTERVENTIONS: After admission, the patient was provided compound glycyrrhizin, Newtide formula milk supplemented with probiotics, fat-soluble vitamins, oral medication to adjust the spleen and stomach, and other symptomatic treatments. OUTCOMES: The stool traits improved, and the levels of liver function transaminases decreased compared with before. LESSONS: SDS is a rare disease with a variety of clinical manifestations. Pancreatic exocrine dysfunction, blood system manifestations, and bone abnormalities are common clinical manifestations, and genetic testing is helpful for diagnosis.


Subject(s)
Bone and Bones/abnormalities , Growth Disorders/etiology , Pancreas, Exocrine/physiopathology , Shwachman-Diamond Syndrome/genetics , Anti-Inflammatory Agents/therapeutic use , Exocrine Pancreatic Insufficiency/diagnosis , Exocrine Pancreatic Insufficiency/etiology , Exocrine Pancreatic Insufficiency/genetics , Female , Glycyrrhizic Acid/therapeutic use , Growth Disorders/genetics , Heterozygote , Humans , Infant , Mutation/genetics , Shwachman-Diamond Syndrome/diagnosis , Shwachman-Diamond Syndrome/therapy , Transaminases/blood , Transaminases/genetics , Treatment Outcome
4.
Nat Commun ; 10(1): 1884, 2019 04 23.
Article in English | MEDLINE | ID: mdl-31015495

ABSTRACT

DNA methyltransferases (DNMTs) deposit DNA methylation, which regulates gene expression and is essential for mammalian development. Histone post-translational modifications modulate the recruitment and activity of DNMTs. The PWWP domains of DNMT3A and DNMT3B are posited to interact with histone 3 lysine 36 trimethylation (H3K36me3); however, the functionality of this interaction for DNMT3A remains untested in vivo. Here we present a mouse model carrying a D329A point mutation in the DNMT3A PWWP domain. The mutation causes dominant postnatal growth retardation. At the molecular level, it results in progressive DNA hypermethylation across domains marked by H3K27me3 and bivalent chromatin, and de-repression of developmental regulatory genes in adult hypothalamus. Evaluation of non-CpG methylation, a marker of de novo methylation, further demonstrates the altered recruitment and activity of DNMT3AD329A at bivalent domains. This work provides key molecular insights into the function of the DNMT3A-PWWP domain and role of DNMT3A in regulating postnatal growth.


Subject(s)
Chromatin/metabolism , DNA (Cytosine-5-)-Methyltransferases/genetics , DNA Methylation/physiology , Gene Expression Regulation, Developmental , Growth Disorders/genetics , Animals , Animals, Newborn , DNA Methyltransferase 3A , Disease Models, Animal , Female , Gain of Function Mutation/physiology , Growth Disorders/pathology , Histones/metabolism , Humans , Hypothalamus/metabolism , Hypothalamus/pathology , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Point Mutation/physiology , Protein Binding/genetics , Protein Domains/genetics , Protein Processing, Post-Translational/physiology
5.
Metallomics ; 9(10): 1352-1366, 2017 10 18.
Article in English | MEDLINE | ID: mdl-28665435

ABSTRACT

Breast milk is the optimal nutrient mix for infants until the age of 6 months. However, in some cases, due to genetic alterations as well as nutrient deficiencies in nursing mothers, infants may suffer from inadequate levels of micronutrients upon exclusive breastfeeding. In this respect, transient neonatal zinc deficiency (TNZD) is caused by loss-of-function mutations in the zinc transporter SLC30A2/ZnT2 gene, resulting in poor secretion of zinc into the breast milk. Consequently, infants exclusively breastfed with zinc-deficient breast milk develop severe zinc deficiency. The main initial symptoms of zinc deficiency are dermatitis, diarrhea, alopecia, and loss of appetite. Importantly, zinc supplementation of these zinc-deficient infants effectively and rapidly resolves these TNZD symptoms. In the current review, we present the major steps towards the identification of the molecular mechanisms underlying TNZD and propose novel approaches that could be implemented in order to achieve an early diagnosis of TNZD towards the prevention of TNZD morbidity. We also discuss the importance of assessing the prevalence of TNZD in the general population, while taking into consideration its autosomal dominant inheritance that was recently established, also supported by a large number of SLC30A2/ZnT2 variants recently identified in American lactating mothers. These findings indicating that TNZD is more frequent than initially thought, along with the increasing number of TNZD cases that were recently reported worldwide, prompted us here to highlight the importance of early diagnosis of SLC30A2/ZnT2 variants in order to supplement zinc-deficient infants in real-time, thus preventing TNZD morbidity and enhancing newborn health. This early genetic diagnosis of zinc deficiency could possibly prove to be a useful platform for the identification of other micronutrient deficiencies, which could be readily resolved by proper real-time supplementation of the infant's diet.


Subject(s)
Cation Transport Proteins/genetics , Growth Disorders/physiopathology , Metal Metabolism, Inborn Errors , Milk, Human/chemistry , Zinc/deficiency , Female , Growth Disorders/genetics , Humans , Mutation
6.
Eur J Endocrinol ; 174(2): 125-36, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26543054

ABSTRACT

OBJECTIVE: Hereditary hypophosphatemias (HH) are rare monogenic conditions characterized by decreased renal tubular phosphate reabsorption. The aim of this study was to explore the prevalence, genotypes, phenotypic spectrum, treatment response, and complications of treatment in the Norwegian population of children with HH. DESIGN: Retrospective national cohort study. METHODS: Sanger sequencing and multiplex ligand-dependent probe amplification analysis of PHEX and Sanger sequencing of FGF23, DMP1, ENPP1KL, and FAM20C were performed to assess genotype in patients with HH with or without rickets in all pediatric hospital departments across Norway. Patients with hypercalcuria were screened for SLC34A3 mutations. In one family, exome sequencing was performed. Information from the patients' medical records was collected for the evaluation of phenotype. RESULTS: Twety-eight patients with HH (18 females and ten males) from 19 different families were identified. X-linked dominant hypophosphatemic rickets (XLHR) was confirmed in 21 children from 13 families. The total number of inhabitants in Norway aged 18 or below by 1st January 2010 was 1,109,156, giving an XLHR prevalence of ∼1 in 60,000 Norwegian children. FAM20C mutations were found in two brothers and SLC34A3 mutations in one patient. In XLHR, growth was compromised in spite of treatment with oral phosphate and active vitamin D compounds, with males tending to be more affected than females. Nephrocalcinosis tended to be slightly more common in patients starting treatment before 1 year of age, and was associated with higher average treatment doses of phosphate. However, none of these differences reached statistical significance. CONCLUSIONS: We present the first national cohort of HH in children. The prevalence of XLHR seems to be lower in Norwegian children than reported earlier.


Subject(s)
Growth Disorders , Hypophosphatemia, Familial , Nephrocalcinosis , Registries , Adolescent , Child , Child, Preschool , Familial Hypophosphatemic Rickets/complications , Familial Hypophosphatemic Rickets/drug therapy , Familial Hypophosphatemic Rickets/epidemiology , Familial Hypophosphatemic Rickets/genetics , Female , Fibroblast Growth Factor-23 , Genotype , Growth Disorders/drug therapy , Growth Disorders/epidemiology , Growth Disorders/etiology , Growth Disorders/genetics , Humans , Hypophosphatemia, Familial/complications , Hypophosphatemia, Familial/drug therapy , Hypophosphatemia, Familial/epidemiology , Hypophosphatemia, Familial/genetics , Infant , Male , Nephrocalcinosis/drug therapy , Nephrocalcinosis/epidemiology , Nephrocalcinosis/etiology , Nephrocalcinosis/genetics , Norway/epidemiology , Pedigree , Phenotype , Phosphorus/therapeutic use , Prevalence , Retrospective Studies , Sex Factors , Vitamin D/therapeutic use
7.
Am J Physiol Gastrointest Liver Physiol ; 310(4): G285-93, 2016 Feb 15.
Article in English | MEDLINE | ID: mdl-26660539

ABSTRACT

Riboflavin (RF) is indispensable for normal cell metabolism, proliferation, and growth. The RFVT-3 protein (product of the Slc52a3 gene) is expressed in the gut with the expression being restricted to the apical membrane domain of the polarized intestinal epithelial cells. The relative contribution of RFVT-3 to total carrier-mediated RF uptake in the native intestine, however, is not clear. We addressed this issue in the current investigation using a conditional (intestinal-specific) RFVT-3 knockout (cKO) mouse model developed by the Cre/Lox approach. All RFVT-3 cKO mice were found to be RF deficient and showed a significant growth and development retardation; also, nearly two-thirds of them died prematurely between the age of 6 and 12 wk. In vivo (intestinal and colonic loops) and in vitro (native isolated intestinal epithelial cells) uptake studies showed a severe inhibition in carrier-mediated RF uptake in the cKO mice compared with control littermates. We also observed a significant increase in the level of expression of oxidative stress-responsive genes in the intestine of the cKO mice compared with control littermates. Supplementation of the RFVT-3 cKO mice with pharmacological doses of RF led to a complete correction of the growth retardation and to normalization in the level of expression of the oxidative stress-responsive genes in the gut. These results show, for the first time, that the RFVT-3 system is the main transporter involved in carrier-mediated RF uptake in the native mouse small and large intestine, and that its dysfunction impairs normal RF body homeostasis.


Subject(s)
Intestinal Absorption/genetics , Membrane Transport Proteins/genetics , Membrane Transport Proteins/metabolism , Riboflavin/metabolism , Vitamins/metabolism , Animals , Colon/metabolism , Developmental Disabilities/genetics , Epithelial Cells/metabolism , Gene Expression/genetics , Growth Disorders/genetics , Homeostasis/genetics , Intestinal Mucosa/metabolism , Mice , Mice, Inbred C57BL , Mice, Knockout , Oxidative Stress/genetics
8.
J Nutr Sci Vitaminol (Tokyo) ; 61 Suppl: S44-6, 2015.
Article in English | MEDLINE | ID: mdl-26598882

ABSTRACT

Zinc nutrition is of special practical importance in infants and children. Poor zinc absorption causes zinc deficiency, which leads to a broad range of consequences such as alopecia, diarrhea, skin lesions, taste disorders, loss of appetite, impaired immune function and neuropsychiatric changes and growth retardation, thus potentially threatening life in infants and children. In addition to dietary zinc deficiency, inherited zinc deficiency, which rarely occurs, is found during the infant stage and early childhood. Recent molecular genetic studies have identified responsible genes for two inherited zinc deficiency disorders, acrodermatitis enteropathica (AE) and transient neonatal zinc deficiency (TNZD), clarifying the pathological mechanisms. Both of these zinc deficiencies are caused by mutations of zinc transporters, although the mechanisms are completely different. AE is an autosomal recessive disorder caused by mutations of the ZIP4 gene, consequently resulting in defective absorption of zinc in the small intestine. In contrast, TNZD is a disorder caused by mutations of the ZnT2 gene, which results in low zinc breast milk in the mother, consequently causing zinc deficiency in the breast-fed infant. In both cases, zinc deficiency symptoms are ameliorated by a daily oral zinc supplementation for the patients. Zinc is definitely one of the key factors for the healthy growth of infants and children, and thus zinc nutrition should receive much attention.


Subject(s)
Acrodermatitis/genetics , Genetic Predisposition to Disease , Growth Disorders/genetics , Milk, Human/chemistry , Zinc/deficiency , Acrodermatitis/blood , Breast Feeding , Cation Transport Proteins/genetics , Child, Preschool , Dietary Supplements , Growth Disorders/blood , Humans , Infant , Nutritional Requirements , Zinc/administration & dosage , Zinc/blood
9.
PLoS One ; 10(7): e0131157, 2015.
Article in English | MEDLINE | ID: mdl-26153892

ABSTRACT

CONTEXT: Hereditary 1,25-dihydroxyvitamin D-resistant rickets (HVDRR) is an autosomal recessive disease caused by biallelic mutations in the vitamin D receptor (VDR) gene. No patients have been reported with uniparental disomy (UPD). OBJECTIVE: Using genome-wide single nucleotide polymorphism (SNP) array to confirm whether HVDRR was caused by UPD of chromosome 12. MATERIALS AND METHODS: A 2-year-old girl with alopecia and short stature and without any family history of consanguinity was diagnosed with HVDRR by typical laboratory data findings and clinical features of rickets. Sequence analysis of VDR was performed, and the origin of the homozygous mutation was investigated by target SNP sequencing, short tandem repeat analysis, and genome-wide SNP array. RESULTS: The patient had a homozygous p.Arg73Ter nonsense mutation. Her mother was heterozygous for the mutation, but her father was negative. We excluded gross deletion of the father's allele or paternal discordance. Genome-wide SNP array of the family (the patient and her parents) showed complete maternal isodisomy of chromosome 12. She was successfully treated with high-dose oral calcium. CONCLUSIONS: This is the first report of HVDRR caused by UPD, and the third case of complete UPD of chromosome 12, in the published literature. Genome-wide SNP array was useful for detecting isodisomy and the parental origin of the allele. Comprehensive examination of the homozygous state is essential for accurate genetic counseling of recurrence risk and appropriate monitoring for other chromosome 12 related disorders. Furthermore, oral calcium therapy was effective as an initial treatment for rickets in this instance.


Subject(s)
Chromosomes, Human, Pair 12 , Polymorphism, Single Nucleotide , Rickets, Hypophosphatemic/diagnosis , Rickets, Hypophosphatemic/genetics , Uniparental Disomy/genetics , Vitamin D/analogs & derivatives , Administration, Oral , Alleles , Alopecia/genetics , Body Height , Calcium/administration & dosage , Child, Preschool , Dietary Supplements , Female , Genome, Human , Growth Disorders/genetics , Heterozygote , Homozygote , Humans , Hydroxycholecalciferols/administration & dosage , Mutation , Vitamin D/metabolism
10.
J Nutr Sci Vitaminol (Tokyo) ; 59(1): 45-55, 2013.
Article in English | MEDLINE | ID: mdl-23535539

ABSTRACT

The present study was conducted to identify reliable gene biomarkers for the adverse effects of excessive leucine (Leu) in Sprague-Dawley rats by DNA microarray. It has long been known that the adverse effects of excessive amino acid intake depend on dietary protein levels. Male rats were divided into 12 groups (n=6) and fed for 1 wk a diet containing low (6%), moderate (12%) or high (40%) protein. Different levels of Leu (0, 2, 4, and 8%) were added to the diets. Consumption of diets containing more than 4% Leu in 6% protein resulted in growth retardation and reduced liver weight, whereas the administration of the same dose of Leu with 12% or 40% protein did not affect them. By a process of systematic data extraction, 6 candidate gene markers were identified. The liver gene expression data obtained from another experiment with 0, 2, 3, 4, and 8% Leu in a low-protein diet was used to examine the validity of these biomarker candidates with receiver operating characteristic (ROC) curve analysis. All of AUC values of the biomarker candidates were more than 0.700, suggesting the effectiveness of the marker candidates as the indices of Leu excess. The cut-off value for the ROC curve of the gene-marker panel, which was obtained by multiple regression analysis of gene markers, indicated that Leu levels higher than 3% have adverse effects. In conclusion, the gene-marker panel suggested that for male rats dietary Leu supplementation of 2% is the NOAEL dose in low-protein (6%) diets.


Subject(s)
Diet, Protein-Restricted , Dietary Proteins/administration & dosage , Dietary Supplements , Energy Intake , Growth Disorders/etiology , Leucine/adverse effects , Liver/drug effects , Animals , Area Under Curve , Biomarkers/metabolism , DNA/analysis , Diet , Dose-Response Relationship, Drug , Gene Expression/drug effects , Genetic Markers , Growth/drug effects , Growth/genetics , Growth Disorders/genetics , Growth Disorders/metabolism , Leucine/administration & dosage , Male , Microarray Analysis , Organ Size , ROC Curve , Rats , Rats, Sprague-Dawley , Reference Values , Regression Analysis , Transcriptome
11.
J Pediatr Gastroenterol Nutr ; 55(3): 292-8, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22331013

ABSTRACT

OBJECTIVE: We conducted a nationwide survey to determine the prevalence of common gastrointestinal and nutritional disorders in Rett syndrome (RTT) based on parental reporting and related the occurrence of these problems to age and methyl-CpG-binding protein 2 (MECP2) gene status. METHODS: We designed a questionnaire that probed symptoms, diagnoses, diagnostic tests, and treatment interventions related to gastrointestinal and nutritional problems in RTT. The International Rett Syndrome Foundation distributed the questionnaire to 1666 family-based members and forwarded their responses for our review. We interrogated the Rare Disease Clinical Research Network database to supplement findings related to medications used to treat gastrointestinal problems in RTT. RESULTS: Parents of 983 female patients with RTT (59%) responded and identified symptoms and diagnoses associated with gastrointestinal dysmotility (92%), chewing and swallowing difficulties (81%), weight deficits or excess (47%), growth deficits (45%), low bone mineral content or fractures (37%), and biliary tract disorders (3%). Height-for-age, weight-for-age, and body mass index z scores decreased significantly with age; height- and weight-, but not body mass index-for-age z scores were significantly lower in female subjects with MECP2 mutations than in those without. Vomiting, nighttime awakening, gastroesophageal reflux, chewing difficulty, and choking with feeding were significantly less likely to occur with increasing age. Short stature, low bone mineral content, fractures, and gastrostomy placement were significantly more likely to occur with increasing age. Chewing difficulty, choking with feeding, and nighttime awakening were significantly less likely to occur, whereas short stature was significantly more likely to occur, in female subjects with MECP2 mutations than in those without. Diagnostic evaluations and therapeutic interventions were used less frequently than the occurrence of symptoms or diagnoses in the RTT cohort. CONCLUSIONS: Gastrointestinal and nutritional problems perceived by parents are prevalent throughout life in girls and women with RTT and may pose a substantial medical burden for their caregivers. Physician awareness of these features of RTT may improve the health and quality of life of individuals affected with this disorder.


Subject(s)
Gastrointestinal Diseases/etiology , Growth Disorders/etiology , Methyl-CpG-Binding Protein 2/genetics , Nutrition Disorders/etiology , Rett Syndrome/complications , Adolescent , Adult , Age Factors , Bone Diseases/complications , Bone Diseases/epidemiology , Child , Child Nutrition Disorders/epidemiology , Child Nutrition Disorders/etiology , Child Nutrition Disorders/genetics , Child, Preschool , Female , Gastrointestinal Diseases/epidemiology , Gastrointestinal Diseases/genetics , Growth Disorders/epidemiology , Growth Disorders/genetics , Health Surveys , Humans , Infant , Infant Nutrition Disorders/epidemiology , Infant Nutrition Disorders/etiology , Infant Nutrition Disorders/genetics , Male , Mutation , Nutrition Disorders/epidemiology , Nutrition Disorders/genetics , Parents , Prevalence , Rett Syndrome/genetics , Surveys and Questionnaires , Young Adult
12.
Clinics (Sao Paulo) ; 67(1): 11-8, 2012.
Article in English | MEDLINE | ID: mdl-22249475

ABSTRACT

OBJECTIVE: Apolipoprotein E4 may benefit children during early periods of life when the body is challenged by infection and nutritional decline. We examined whether apolipoprotein E4 affects intestinal barrier function, improving short-term growth and long-term cognitive outcomes in Brazilian shantytown children. METHODS: A total of 213 Brazilian shantytown children with below-median height-for-age z-scores (HAZ) received 200,000 IU of retinol (every four months), zinc (40 mg twice weekly), or both for one year, with half of each group receiving glutamine supplementation for 10 days. Height-for-age z-scores, weight-for-age z-scores, weight-for-height z-scores, and lactulose:mannitol ratios were assessed during the initial four months of treatment. An average of four years (range 1.4-6.6) later, the children underwent cognitive testing to evaluate non-verbal intelligence, coding, verbal fluency, verbal learning, and delayed verbal learning. Apolipoprotein E4 carriage was determined by PCR analysis for 144 children. RESULTS: Thirty-seven children were apolipoprotein E4(+), with an allele frequency of 13.9%. Significant associations were found for vitamin A and glutamine with intestinal barrier function. Apolipoprotein E4(+) children receiving glutamine presented significant positive Pearson correlations between the change in height-for-age z-scores over four months and delayed verbal learning, along with correlated changes over the same period in weight-for-age z-scores and weight-for-height z-scores associated with non-verbal intelligence quotients. There was a significant correlation between vitamin A supplementation of apolipoprotein E4(+) children and improved delta lactulose/mannitol. Apolipoprotein E4(-) children, regardless of intervention, exhibited negative Pearson correlations between the change in lactulose-to-mannitol ratio over four months and verbal learning and non-verbal intelligence. CONCLUSIONS: During development, apolipoprotein E4 may function concomitantly with gut-tropic nutrients to benefit immediate nutritional status, which can translate into better long-term cognitive outcomes.


Subject(s)
Apolipoprotein E4/genetics , Cognition/drug effects , Diarrhea/drug therapy , Growth Disorders/genetics , Malnutrition/drug therapy , Micronutrients/administration & dosage , Apolipoprotein E4/drug effects , Brazil , Child, Preschool , Diarrhea/metabolism , Diarrhea/psychology , Female , Gene Frequency/drug effects , Gene Frequency/genetics , Glutamine/administration & dosage , Growth Disorders/metabolism , Humans , Intestinal Absorption/drug effects , Intestinal Absorption/genetics , Lactulose , Male , Malnutrition/metabolism , Malnutrition/psychology , Mannitol , Permeability/drug effects , Poverty Areas , Prospective Studies , Vitamin A/administration & dosage , Zinc/administration & dosage
13.
J Pediatr Endocrinol Metab ; 25(11-12): 1191-4, 2012.
Article in English | MEDLINE | ID: mdl-23329770

ABSTRACT

Chylomicron retention disease (CRD), or Anderson disease, is a rare, hereditary cause of fat malabsorption. It is one of the familial hypocholesterolaemia syndromes, along with homozygous hypobetalipoproteinaemia (HBL) and abetalipoproteinaemia (ABL). We report clinical, laboratory and histological data as well as molecular DNA analysis in the case of a 4-month-old boy with failure to thrive and steatorrhea who was diagnosed with CRD. His mother's first cousin, who was diagnosed as hypobetalipoproteinaemia 30 years ago, was also reviewed and his diagnosis was revised to CRD. Both patients were treated with a low fat diet and supplementation with fat-soluble vitamins resulting in significant improvement. In conclusion, CRD is a well-defined cause of fat malabsorption and can be distinguished from other forms of familial hypocholesterolaemia because of its specific lipid profile.


Subject(s)
Chylomicrons/metabolism , Failure to Thrive/diagnosis , Growth Disorders/diagnosis , Lipid Metabolism Disorders/diagnosis , Malabsorption Syndromes/diagnosis , Diet, Fat-Restricted , Dietary Supplements , Duodenum/pathology , Duodenum/ultrastructure , Endoscopy, Gastrointestinal , Failure to Thrive/genetics , Failure to Thrive/metabolism , Family Health , Growth Disorders/genetics , Growth Disorders/metabolism , Humans , Infant , Lipid Metabolism Disorders/genetics , Lipid Metabolism Disorders/metabolism , Malabsorption Syndromes/genetics , Malabsorption Syndromes/metabolism , Male , Steatorrhea/diagnosis , Steatorrhea/genetics , Steatorrhea/metabolism , Vitamins/administration & dosage
14.
Clinics ; 67(1): 11-18, 2012. ilus, tab
Article in English | LILACS | ID: lil-610618

ABSTRACT

OBJECTIVE: Apolipoprotein E4 may benefit children during early periods of life when the body is challenged by infection and nutritional decline. We examined whether apolipoprotein E4 affects intestinal barrier function, improving short-term growth and long-term cognitive outcomes in Brazilian shantytown children. METHODS: A total of 213 Brazilian shantytown children with below-median height-for-age z-scores (HAZ) received 200,000 IU of retinol (every four months), zinc (40 mg twice weekly), or both for one year, with half of each group receiving glutamine supplementation for 10 days. Height-for-age z-scores, weight-for-age z-scores, weight-forheight z-scores, and lactulose:mannitol ratios were assessed during the initial four months of treatment. An average of four years (range 1.4-6.6) later, the children underwent cognitive testing to evaluate non-verbal intelligence, coding, verbal fluency, verbal learning, and delayed verbal learning. Apolipoprotein E4 carriage was determined by PCR analysis for 144 children. RESULTS: Thirty-seven children were apolipoprotein E4(+), with an allele frequency of 13.9 percent. Significant associations were found for vitamin A and glutamine with intestinal barrier function. Apolipoprotein E4(+) children receiving glutamine presented significant positive Pearson correlations between the change in height-for-age z-scores over four months and delayed verbal learning, along with correlated changes over the same period in weight-for-age z-scores and weight-for-height z-scores associated with non-verbal intelligence quotients. There was a significant correlation between vitamin A supplementation of apolipoprotein E4(+) children and improved delta lactulose/mannitol. Apolipoprotein E4(-) children, regardless of intervention, exhibited negative Pearson correlations between the change in lactulose-to-mannitol ratio over four months and verbal learning and non-verbal intelligence. CONCLUSIONS: During development, apolipoprotein E4 may function concomitantly with gut-tropic nutrients to benefit immediate nutritional status, which can translate into better long-term cognitive outcomes.


Subject(s)
Child, Preschool , Female , Humans , Male , /genetics , Cognition/drug effects , Diarrhea/drug therapy , Growth Disorders/genetics , Malnutrition/drug therapy , Micronutrients/administration & dosage , /drug effects , Brazil , Diarrhea/metabolism , Diarrhea/psychology , Gene Frequency/drug effects , Gene Frequency/genetics , Glutamine/administration & dosage , Growth Disorders/metabolism , Intestinal Absorption/drug effects , Intestinal Absorption/genetics , Lactulose , Malnutrition/metabolism , Malnutrition/psychology , Mannitol , Poverty Areas , Prospective Studies , Permeability/drug effects , Vitamin A/administration & dosage , Zinc/administration & dosage
15.
J Pediatr Endocrinol Metab ; 24(7-8): 569-71, 2011.
Article in English | MEDLINE | ID: mdl-21932602

ABSTRACT

A 10.5-year-old Caucasian girl with familial glucocorticoid deficiency (FGD) is presented. She had a homozygous S74I mutation of the ACTH receptor and her parents were heterozygous for the same mutation. Around 4 years prior to the diagnosis of FGD, she was diagnosed with antibody positive primary hypothyroidism and was on thyroxin supplementation. FGD patients are considered to be tall. Our patient was only 146.5 cm (4' 9.25") tall at age 17 years (-2.21 standard deviations below the mean for her age). The possible mechanism for short stature in FGD is speculated.


Subject(s)
Adrenal Insufficiency/congenital , Adrenal Insufficiency/complications , Congenital Hypothyroidism/complications , Glucocorticoids/deficiency , Growth Disorders/genetics , Adrenal Insufficiency/drug therapy , Adrenal Insufficiency/genetics , Body Height/drug effects , Child , Child Development/drug effects , Family Health , Female , Hormone Replacement Therapy , Humans , Mutation , Thyroxine/therapeutic use , Treatment Outcome
16.
Food Nutr Bull ; 30(3): 245-53, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19927604

ABSTRACT

BACKGROUND: Previous growth studies of Peruvian children have featured high stunting rates and limited information about body composition. OBJECTIVE: We aimed to characterize anthropometric measures of Peruvian infants 0 to 12 months of age in relation to the international growth references and biological, environmental, and socioeconomic factors. METHODS: Infants (n = 232) were followed longitudinally from birth through 12 months of age from a prenatal zinc supplementation trial conducted in Lima, Peru, between 1995 and 1997. Anthropometric measures of growth and body composition were obtained at enrollment from mothers and monthly through 1 year of age from infants. Weekly morbidity and dietary intake surveillance was carried out during the second half of infancy. RESULTS: The prevalence rates of stunting, underweight, and wasting did not exceed 4% based on the World Health Organization growth references. Infants of mothers from high-altitude regions had larger chest circumference (p = .006) and greater length (p = .06) by 12 months. Significant predictors of growth and body composition throughout infancy were age, sex, anthropometric measurements at birth, breastfeeding, maternal anthropometric measurements, primiparity, prevalence of diarrhea among children, and the altitude of the region of maternal origin. No associations were found for maternal education, asset ownership, or sanitation and hygiene factors. CONCLUSIONS: Peruvian infants in this urban setting had lower rates of stunting than expected. Proximal and familial conditions influenced growth throughout infancy.


Subject(s)
Body Composition , Body Size , Growth Disorders/epidemiology , Poverty/statistics & numerical data , Urban Health/statistics & numerical data , Aging , Body Weights and Measures/statistics & numerical data , Diet , Female , Growth Disorders/genetics , Humans , Infant , Infant, Newborn , Longitudinal Studies , Male , Peru/epidemiology , Prevalence , Reference Values , Regression Analysis , Sex Characteristics , Socioeconomic Factors
17.
Rev. chil. endocrinol. diabetes ; 2(3): 173-178, jul. 2009. ilus, tab
Article in Spanish | LILACS | ID: lil-610296

ABSTRACT

Human growth is a complex process regulated by several genes, most of which are unknown. Recently, our knowledge regarding the etiology of genetically determined causes of short stature has greatly increased, so molecular analysis is becoming essential for the diagnosis of growth retardation. The advances in our understanding of the molecular mechanisms involved in the function of the somatotrophic axis have resulted in a dramatic enhancement of our ability to diagnose and treat growth disorders. We hope that in the next few years improved methods for identifying specific abnormalities which cause short stature will expand our ability to diagnose other causes of growth retardation, and reduce the proportion of patients with "idiopathic" short stature.


Subject(s)
Humans , Body Height/genetics , Growth Hormone/genetics , Growth Disorders/diagnosis , Growth Disorders/genetics , Insulin-Like Growth Factor I/physiology , Insulin-Like Growth Factor I/genetics , Pituitary Gland/physiology , Hypothalamus/physiology , Growth Hormone-Releasing Hormone/physiology , Growth Hormone-Releasing Hormone/genetics , Growth Hormone/physiology , Mutation
18.
Endocrinology ; 149(9): 4382-6, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18499759

ABSTRACT

The GH/IGF-I axis plays a critical role in mammalian body growth. GH is secreted by the anterior pituitary, and its actions are primarily mediated by IGF-I that is secreted by the liver and other tissues. Local and circulating IGF-I action is largely mediated by the phosphoinositide 3-kinase signaling pathway, and phosphatase with tensin homology (PTEN) is a potent negative regulator of this pathway. Here we show that RIPcre+Ptenfl/fl mice, which exhibit PTEN deletion in insulin-transcribing neurons of the hypothalamus in addition to pancreatic beta-cells, result in a small-body phenotype that is associated with an unexpected increase in serum IGF-I levels. We tested whether exogenous GH can override the growth defect in RIPcre+Ptenfl/fl mice. Our results showed no significant difference in their growth between the RIPcre+Ptenfl/fl mice injected with GH or vehicle. Together, PTEN in the hypothalamic insulin-transcribing neurons plays an essential role in body size determination, and systemic GH cannot overcome the growth defect in these mice.


Subject(s)
Growth Disorders/drug therapy , Growth Disorders/genetics , Growth Hormone/therapeutic use , Hypothalamus/metabolism , PTEN Phosphohydrolase/genetics , Animals , Body Size/genetics , Drug Resistance/genetics , Female , Gene Deletion , Growth Disorders/pathology , Insulin/genetics , Insulin/metabolism , Insulin-Like Growth Factor Binding Protein 1/blood , Insulin-Like Growth Factor Binding Protein 1/genetics , Insulin-Like Growth Factor Binding Protein 1/metabolism , Insulin-Like Growth Factor Binding Protein 3/blood , Insulin-Like Growth Factor Binding Protein 3/genetics , Insulin-Like Growth Factor Binding Protein 3/metabolism , Insulin-Like Growth Factor I/analysis , Insulin-Like Growth Factor I/genetics , Insulin-Like Growth Factor I/metabolism , Liver/metabolism , Liver/pathology , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , PTEN Phosphohydrolase/metabolism , RNA, Messenger/metabolism , Treatment Failure
19.
Am J Kidney Dis ; 48(5): e73-9, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17059986

ABSTRACT

We report a case of Gitelman syndrome (GS) in a dizygotic twin who presented at 12 years of age with growth delay, metabolic alkalosis, hypomagnesemia and hypokalemia with inappropriate kaliuresis, and idiopathic intracranial hypertension with bilateral papilledema (pseudotumor cerebri). The patient, her twin sister, and her mother also presented with cerebral cavernous malformations. Based on the early onset and normocalciuria, Bartter syndrome was diagnosed first. However, mutation analysis showed that the proband is a compound heterozygote for 2 mutations in SLC12A3: a substitution of serine by leucine at amino acid position 555 (p.Ser555Leu) and a novel guanine to cytosine transition at the 5' splice site of intron 22 (c.2633+1G>C), providing the molecular diagnosis of GS. These mutations were not detected in 200 normal chromosomes and cosegregated within the family. Analysis of complementary DNA showed that the heterozygous nucleotide change c.2633+1G>C caused the appearance of 2 RNA molecules, 1 normal transcript and 1 skipping the entire exon 22 (r.2521_2634del). Supplementation with potassium and magnesium improved clinical symptoms and resulted in catch-up growth, but vision remained impaired. Three similar associations of Bartter syndrome/GS with pseudotumor cerebri were found in the literature, suggesting that electrolyte abnormalities and secondary aldosteronism may have a role in idiopathic intracranial hypertension. This study provides further evidence for the phenotypical heterogeneity of GS and its association with severe manifestations in children. It also shows the independent segregation of familial cavernomatosis and GS.


Subject(s)
Diseases in Twins/genetics , Gitelman Syndrome/genetics , Protein Splicing/genetics , Pseudotumor Cerebri/genetics , Receptors, Drug/genetics , Symporters/genetics , Alkalosis/genetics , Bartter Syndrome/genetics , Child , DNA Mutational Analysis , Diuretics , Female , Growth Disorders/genetics , Humans , Hypokalemia/genetics , Magnesium Deficiency/genetics , Magnetic Resonance Imaging , Mutation , Pedigree , Pseudotumor Cerebri/complications , Pseudotumor Cerebri/diagnosis , Solute Carrier Family 12, Member 3 , Syndrome
20.
J Clin Endocrinol Metab ; 91(8): 3062-70, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16757531

ABSTRACT

CONTEXT: The type 1 IGF-I receptor (IGF1R) mediates the biological functions of IGF-I. Binding of IGF-I to the IGF1R results in autophosphorylation of the intracellular beta-subunit and activation of intracellular signaling. OBJECTIVE: The objective of this study was to evaluate the functional characteristics of a novel IGF1R mutation and describe the phenotypic features of two patients with this mutation. DESIGN: The study was performed in a university hospital. PATIENTS: We describe a 35-yr-old female with mild intrauterine growth failure, progressive postnatal growth retardation, severe failure to thrive, and microcephaly. Her daughter was born with severe intrauterine growth retardation and also showed postnatal failure to thrive and microcephaly. RESULTS: We found a heterozygous G3148-->A nucleotide substitution in the IGF1R gene, changing a negatively charged glutamic acid at position 1050 into a positively charged lysine residue (E1050K). E1050 is a conserved residue in the intracellular kinase domain. Dermal fibroblasts of the mother showed normal binding of iodinated IGF-I, but autophosphorylation and activation of downstream signaling cascades upon challenging with IGF-I was markedly reduced. Consequently, the maximal [(3)H]thymidine incorporation upon challenge with a dose range of IGF-I was reduced compared with a panel of control cells (3.65 +/- 1.79-fold vs. 6.75 +/- 4.7-fold stimulation; P < 0.01). These data suggest that the mutation results in the inactivation of one copy of the IGF1R gene. CONCLUSIONS: These two patients support the key role for IGF-I in intrauterine and postnatal growth. The different phenotypes of these and earlier described patients may be associated with variability in IGF-I signaling. The degree of intrauterine growth retardation may be partially determined by the presence or absence of maternal IGF-I resistance.


Subject(s)
Fetal Growth Retardation/genetics , Growth Disorders/genetics , Mutation, Missense/genetics , Receptor, IGF Type 1/genetics , Adult , Base Sequence , Body Height , Bone Density , DNA Mutational Analysis , DNA, Complementary/chemistry , Failure to Thrive/genetics , Female , Fibroblasts/metabolism , Glutamic Acid , Heterozygote , Humans , Infant , Insulin-Like Growth Factor I/analysis , Insulin-Like Growth Factor I/metabolism , Insulin-Like Growth Factor I/pharmacology , Lysine , Microcephaly/genetics , Phosphorylation , Polymerase Chain Reaction , Receptor, IGF Type 1/physiology , Sequence Analysis, DNA , Signal Transduction/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL